INTERLEUKIN-17A

Approval Year

Substance Class	Protein Created by `admin` on `Tue Apr 01 20:53:30 GMT 2025` Edited by `admin` on `Tue Apr 01 20:53:30 GMT 2025`
Protein Type	CYTOKINE
Protein Sub Type	INTERLEUKINS
Sequence Origin	HUMAN
Sequence Type	COMPLETE
Record UNII	R44E6C7B6J
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CTLA8

Preferred Name

English

INTERLEUKIN-17A

Common Name

English

IL17A

Common Name

English

CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED ANTIGEN 8

Common Name

English

IL-17A

Common Name

English

IL17

Common Name

English

Code System Code Type Description

FDA UNII

R44E6C7B6J

Created by admin on Tue Apr 01 20:53:30 GMT 2025 , Edited by admin on Tue Apr 01 20:53:30 GMT 2025

PRIMARY

UNIPROT

Q16552

Created by admin on Tue Apr 01 20:53:30 GMT 2025 , Edited by admin on Tue Apr 01 20:53:30 GMT 2025

PRIMARY

From	To
2_76	2_123
2_71	2_121
1_71	1_121
1_76	1_123

Glycosylation Type

HUMAN

Glycosylation Link Type	Site
N	1_45
N	2_45

Related Record Type Details


					42HQ15W1ZF

TIBULIZUMAB

INHIBITOR -> TARGET

Amount:


					6YYC67U8QJ

Crusekitug

LIGAND->TARGET

Amount:


					LEN0OCZ4SH

SONELOKIMAB

INHIBITOR -> TARGET


					Y64F9MC2QM

Navepdekinra

INHIBITOR -> TARGET

Interaction Type:

IN-VITRO

Qualification:

IC50


					C28VQU7LB4

Erepdekinra

INHIBITOR -> TARGET

Amount:


					09495UIM6V

BIMEKIZUMAB

INHIBITOR -> TARGET


					8B8VV1W6FZ

IZOKIBEP

INHIBITOR -> TARGET

Amount:


					8X769U9BGL

Amdokitug

LIGAND->TARGET

Amount:


					OIQ1SI09EU

Betinukibart

INHIBITOR -> TARGET

Amount:


					BTY153760O

IXEKIZUMAB

INHIBITOR -> TARGET


					1V8WRH3RVX

REMTOLUMAB

INHIBITOR -> TARGET


					2BQ9Q4ZR51

BITS-7201A

INHIBITOR -> TARGET


					SYT94XC6FQ

APL-1

INHIBITOR OF EXPRESSION->TARGET

Comments:

Reduces the expression of inflammatory cytokines

Amount:


					MD885NVL3Q

Roconkibart

LIGAND->TARGET

Amount:


					34KYN5U7P7

Lecankitug

LIGAND->TARGET

Amount:


					85A4592PC8

Galvokimig

LIGAND->TARGET

Amount:


					A2X6JB3B7U

Turenkibart

INHIBITOR -> TARGET

Amount:


					0994X4C98G

LY-3509754

INHIBITOR -> TARGET

Comments:

Surface plasmon resonance showed extended dissociation half-life of 14.5?hours (association rate constant, 7.22?×?103?M?1?s?1; dissociation rate constant, 1.33?×?10?5?s?1.

Interaction Type:

BINDING

Qualification:

Kd

Amount: